JOSE
CANIVE,
M.D.
Department of
Psychiatry
PROFESSOR OF PSYCHIATRY AND
NEUROSCIENCES
DIRECTOR, PSYCHIATRY RESEARCH CLINICAL NEUROSCIENCE RESEARCH GROUP, VAMC
DIRECTOR, CENTER FOR FUNTIONAL BRAIN IMAGING, VAMC
M.D., Universidad Complutense, Madrid, 1966
Residency: McGill University, Montreal, 1968-72
e-mail: jmcanmd@unm.edu
Description of clinical interests and expertise:
My clinical interests include the phenomenology, pathophysiology and treatment of schizophrenia and PTSD. I am also interested in the access and utilization of mental health services and existing ethnic disparities.
Description of educational and personal interests:
To mentor medical students, graduate students, residents and junior faculty in their research careers.
I love the Fine Arts, especially music. I enjoy playing the piano and singing, and derive great pleasure listening to classical and Latin music. Going to a museum or an art exhibition is enthralling.
Description of scholarly and research interests:
After completing my residency training I worked mostly as a clinician in Vancouver, Canada. In 1978 I decided to move to New Mexico with two main goals in mind: (1) to provide services to Hispanic populations; and (2) to pursue and academic career. I initially worked at one of UNM's Mental Health Center satellite clinics and eventually became Director of the Outpatient Division. I was initially attracted by the field of Cultural Psychiatry and then became fascinated by the new family psychoeducational interventions in schizophrenia and the work of the late Ian Falloon. This led me to spend a sabbatical year at my Alma Mater, Madrid's Universidad Complutense, to adapt Falloon's psychoeducational intervention to people from a different ethnic background. Soon after my return from Madrid I published a few articles on my work and became involved in industry sponsored clinical trials in schizophrenia. In 1991 I moved to the VA as Director of the PTSD Program. Since then my research endeavors have flourished in different ways through: (1) Participating in numerous multicenter clinical trials, investigator initiated studies and real-world, practical trials such as the NIMH sponsored Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE); (2) Examining sensory gating in schizophrenia with magentoencephalography (MEG); (3) Investigating the barriers to mental health care among minority veterans (a joined project with Joseph Westermeyer at the Minneapolis VA); (4) Determining the prevalence of pathological gambling among veterans receiving primary care at two VAMCs (a joined project with Joseph Westermeyer at the Minneapolis VA). The most satisfactory part of my activities has been to mentor graduate students, research fellows and junior faculty and successfully help them obtain Industry Sponsored Investigator Initiated Studies, NARSAD and NIMH funding. I am currently Principal Investigator on a VA MERIT and on an NIMH R01 to further examine the neural substrates of the sensory gating phenomenon. I am also PI on two VA cooperative studies, an NIMH funded clinical trial, several Investigator Initiated Studies and Industry Sponsored Clinical Trials.
Current and Recent Grants:
Current Funding
a. Federal, Private Non-Profit Foundations and Investigator Initiated Studies
VA Merit: “Prefrontal Involvement in Schizophrenia Gating Deficit”
Role: Principal Investigator
Dates of Project: 07/07 – 06/11
VA HSR&D Grant # IIR-04-212-3: “Relationship of General, Behavioral and
Emotional Health among Veterans Receiving VA Health Care”
Role: Co-PI
Dates of Project: 04/06 – 10/08
NARSAD Young Investigator Award: “Genetic Basis of Sensory Gating and Cognitive Impairment”
PI: Brett Lu, MD, PhD
Role:
Mentor and Co-Investigator
Dates of Project: 07/05-07/08
NIMH Grant # N01 MH90001: Clinical Antipsychotic Trials of Intervention Effectiveness II (CATIE II)
PI: Jeffrey A. Lieberman, MD
Role: Site
Principal Investigator
Dates of Project: 07/04-07/08
VA Cooperative Studies: “Risperidone in the Treatment of Combat Veterans with
Severe PTSD”
PIs: John Krystal and Robert Rosenheck
Role: Site Principal Investigator
Dates of Project: 01/07 – 07/09
NIMH R01 Grant # 5 RO1 MH65304-01: “Cortical Basis of Schizophrenia Sensory
Gating”
Role:
Principal Investigator
Dates of Project: 08/02-07/08
Current Federal, Private Non-Profit Funding (continued)
NIH / UNC: "Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to Aripiprazole versus Continued Treatment with Olanzapine, Quetiapine, or Risperidone" CAMP STUDY
Role: Principal Investigator
Dates of Project:
04/07 – 09/09
Eli Lilly Investigator Initiated Study: “Open-Label Duloxetine Monotherapy in the
Treatment of Posttraumatic Stress Disorder”
Role: Principal Investigator
Dates of Project: 01/06 – 12/08
b. Other Current Funding
Janssen / Covance: “A Single-Arm Evaluation of the Safety of Paliperidone Extended-
Release (ER) in Subjects with Schizophrenia or Schizoaffective Disorder with Hepatic
Disease. Protocol R076477-SCH-4005”
Role: Principal Investigator
Dates of Project:
Total Costs:
3. Prior Funding
a. Federal, Private Non-Profit Foundations and Investigator Initiated Studies
American Psychiatric Association Minority Research Fellowship
PI: Brett Lu, MD, PhD
Role: Mentor
Dates of Project: 07/04-07/06
Bristol Myers Squibb, Investigator Initiated Study: “Treatment of the Metabolic Syndrome with Aripiprazole: An Open-Label Trial”
PI: Cynthia Geppert, MD, PhD
Role: Mentor
and Co-Investigator
Dates of Project: 06/04-06/06
MIND Institute: “Assessment of Lateralized Hippocampal Function”
PI: Faith M. Hanlon, PhD
Role: Mentor and Co-Investigator
Dates of Project: 01/05-12/05
NARSAD Young Investigator Award: “Hippocampal Disconnection and Memory Deficits in Schizophrenia”
PI: Michael P. Weisend, PhD
Role: Mentor
and Co-Investigator
Dates of Project: 07/03-07/05
VA VISN 18 Career Development Award: “Sensory Gating in PTSD”
PI: Gerardo Villarreal, MD
Role: Mentor and Co-Investigator
Dates of Project: 05/04-05/05
Prior Funding (continued)
VA VISN 18 Career Development Award: “Internal Working Models of Attachment and PTSD in Combat Veterans”
PI: Ella C. Nye, PhD
Role:
Mentor and Co-Investigator
Dates of Project:
05/04 – 05/05
NIMH R21 Grant # 1R21 MH069965-01A2: “A New Way to Study Cortical Networks in Working Memory”
PI: Michael P. Weisend, PhD
Role:
Co-Investigator
Dates of Project:
12/05-12/07
Total costs: $270,000
NARSAD Young Investigator Award: “Auditory Gating Deficit: Mechanisms of Neural Synchrony”
PI: James C. Edgar, PhD
Role:
Sponsor and Co-Investigator
Dates of Project: 07/05-07/07
NIMH R21 Grant #1R21 MH067287-01A1: “Face Affect Processing in Schizophrenia with MEG”
PI: Stephen F. Lewis, MD
Role: Mentor and Co-Investigator
Dates of Project: 03/05-02/08
Janssen Pharmaceuticals: “Two-Year, Multicenter, Longitudinal Observational Study of Patients with Schizophrenia or Schizoaffective Disorder Treated with Risperdal Consta”
Role:
Principal Investigator
Dates of Project: 05/05-10/06
Pfizer/Organon: “153003, A Multicenter, Randomized, Double-Blind, Fixed-Dose, Efficacy and Safety trial of Org 24448 (250 and 500 mg b.i.d.) vs. placebo as augmentation therapy in schizophrenic subjects currently receiving risperidone (2 or 3 mg b.i.d.)”
Role:
Principal Investigator
Dates of Project: 03/06 – 03/07
Pfizer/Organon: “Protocol A7501013: A Multicenter, Double-Blind, Flexile-Dose, 6-month Trial Comparing the Efficacy and Safety of Asenapine with Olanzapine in Stable Subjects with Predominant Persistent Negative Symptoms of Schizophrenia”
Role: Principal Investigator
Dates of Project: 05/05-04/06
Pfizer/ Organon: “Protocol: A7401014 “A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trail Comparing the Safety and Efficacy of Asenapine with Olanzapine in Subjects Who Complete Protocol A7501013”
Role:
Principal Investigator
Dates of Project: 05/05-12/06
GlaxoSmith Klein: “Protocol NAA104606 A Multi-center, Double-blind, Double-dummy, Placebo-controlled, Randomized, Adaptive, Dose-range Study to Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults with
Schizophrenia”
Role:
Principal Investigator
Dates
of Project: 01/07 – 04/07
Publications since 2002:
1. Westermeyer J, Cañive J, Thuras P, Chesness D, Thompson J: Perceived Barriers to VA Mental Health Care Among Upper Midwest American Indian Veterans: Description and Correlates. Medical Care 40(1), Supplement: 1-10, January 2002.
2. Escalona R, Cañive JM, Calais LA, Davidson JRT: Fluvoxamine Treatment in Veterans with Combat Related Posttraumatic Stress Disorder. Depression and Anxiety, 15:29-33, 2002.
3. Lewine JD, Thoma RJ, Provencal SL, Edgar JC, Miller GA, Cañive JM: Abnormal stimulus-response intensity functions in post-traumatic stress disorder: An electrophysiological investigation. American Journal of Psychiatry, 159(10):1689-1695, 2002.
4. Westermeyer J, Cañive JM, Garrard J, Padilla E, Crosby R, Thuras P: Perceived barriers to mental health care for American Indian and Hispanic veterans: Reports by 100 VA staff. Transcultural Psychiatry, 39(4):516-530, 2002.
5. Thoma RJ, Hanlon FM, Moses SN, Edgar JC, Huang MX, Weisend MP, Irwin J, Sherwood A, Paulson K, Bustillo J, Adler LE, Miller GA, Cañive JM: Lateralization of auditory sensory gating and neuropsychological dysfunction in schizophrenia. American Journal of Psychiatry, 160(9):1595-1605, 2003.
6. Huang M, Thoma RJ, Hanlon F, Edgar JC, Moses S, Paulsen K, Weisend M, Miller GA, Cañive JM: Predicting EEG responses using MEG sources in superior temporal gyrus reveals anomaly in patients with schizophrenia. Clinical Neurophysiology, 114:835-850, 2003.
7. Stroup TS, McEvoy JP, Swartz MS, Byerly M, Glick I, Cañive JM, McGee M, Simpson G, Stevens M, Lieberman JA: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Schizophrenia Trial Design and Protocol Development. Schizophrenia Bulletin, 29(1):15-31, 2003.
8. Cañive JM: Treating schizophrenia in the 'real world.' Current Psychiatry, 2:83-87, 2003.
9. Lewis S, Thoma R, LaNoue MD, Miller GA, Heller W, Edgar JC, Huang M, Weisend M, Irwin J, Paulson K Cañive JM: Visual Processing of Facial Affect. NeuroReport, 14(14): 1841-1845, 2003.
10. Hanlon FM, Weisend MP, Huang M, Lee RR, Moses SN, Paulson KM, Thoma RJ, Miller GA, Cañive JM: A Noninvasive method for observing hippocampal function. NeuroReport, 14(15):1957-1960, 2003.
11. Edgar JC, Huang M, Weisend MP, Sherwood A, Miller GA, Adler LE, Cañive JM: Interpreting Abnormality: An EEG and MEG study of P50. Biological Psychology, 65(1):1-20, 2003.
12. Huang MX, Shih JJ, Lee RR, Harrington DL, Thoma RJ, Weisend MP, Hanlon F, Paulson KM, Li T, Martin K, Miller GA, Cañive JM: Commonalities and differences among vectorized beamformers in electromagnetic source imaging. Brain Topography, 16 (3):139-158, 2004.
13. Thoma RJ, Hanlon FM, Sanchez FM, Weisend MP, Huang M, Jones A, Miller GA, Cañive JM: Auditory Sensory Gating Deficit and Cortical Thickness in Schizophrenia. Journal Neurology and Clinical Neurophysiology, 62:1-7, 2004.
14. Thoma RJ, Hanlon FM, Moses SN, Ricker D, Huang MX, Edgar JC, Irwin J, Torres F, Weisend MP, Adler LE, Miller GA, Cañive JM: M50 sensory gating predicts negative symptoms in schizophrenia. Schizophrenia Research, 73:311-318, 2005.
15. Westermeyer JJ, Cañive JM, Garrard J, Thuras, P, Thompson J: Lifetime prevalence of pathological gambling among American Indian and Hispanic veterans. American Journal of Public Health, 95:860-866, 2005.
16. Edgar JC, Moses S, Thoma RJ, Huang MX, Hanlon F, Weisend MP, Sherwood A, Bustillo J, Adler LE, Miller GA, Cañive JM: Cross-modal generality of the gating deficit in schizophrenia. Psychophysiology, 42:318-327, 2005.
17. Huang MX, Lee RR, Miller GA, Thoma RJ, Hanlon F, Paulson KM, Martin K, Harrington DL, Weisend MP, Cañive JM: A Parietal-Frontal Network Studied by Somatosensory Oddball MEG Responses, and Its Cross-modal Consistency. Neuroimage, 28(1):99-114, 2005.
18. Hanlon FM, Weisend MP, Yeo RA, Huang M, Thoma RJ, Lee RR, Moses SN, Paulson M, Petropoulos H, Miller GA, Cañive, J.M: A specific test of hippocampal deficit in schizophrenia. Behavioral Neuroscience, 119(4):863-875, 2005.
19. Hanlon FM, Miller GA, Thoma RJ, Irwin J, Moses SN, Huang M, Weisend MP, Paulson KM, Edgar JC, Adler LE, Cañive JM: Distinct M50 and M100 auditory gating deficits in schizophrenia. Psychophysiology, 42(4):417-427, 2005.
20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine, 353:12, 1209-1223, 2005.
20. Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J; CATIE Study Investigators Group: Barriers to employment for people with schizophrenia. American Journal of Psychiatry, 163(3):411-417, 2006.
21. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RSE, Swartz M, Perkins DO, Hsiao JK; CATIE Study Investigators Group: Cost-Effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry, 163:2080-2089, 2006.
22. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators Group: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior to atypical antipsychotic treatment. Am J Psychiatry, 163(4):600-610, 2006.
23. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators Group: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry, 163(4):600-610, 2006.
20. Edgar JC, Yeo RA, Gangestad SW, Blake MB, Davis JT, Lewine JD, Cañive JM: Reduced Auditory M100 Asymmetry in Schizophrenia and Dyslexia: Applying a Developmental Instability Approach to Assess Atypical Brain Asymmetry. Neuropsychologia, 44(2):289-299, 2006.
21. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Cañive JM, Miller DD, Reimherr F, McGee M, Kahn A, Van Dorn R, Rosenheck RA, Lieberman JA. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease, 194(3):164-172, 2006.
22. Delgado PL, MD; Alegría M, Canive JM, Diaz E, Escobar JI, Kopelowicz A, Oquendo MA, Ruiz P, Vega W: Depression and its treatment in U.S. Hispanic groups: A review of the literature and recommendations for future research. Focus, IV(1):38-47, 2006.
23. Thoma RJ, Hanlon FM, Huang M, Weisend MP, Formoso MJ, Jones A, Smith A, Sanchez FP, Waldorf VA, Miller GA, Cañive JM: Neuropsychological and Sensory Gating Deficits Related to Remote Alcohol Abuse History in Schizophrenia. Journal of the International Society of Neuropsychology, 12:34-44, 2006.
24. Huang MX, Dale AM, Song T, Halgren E, Harrington DL, Podgorny I, Cañive JM, Lewis S, Lee RR: Vector-based Spatial Temporal Minimum L1-norm Solution for MEG Neuroimage, 31:1025-1037, 2006.
25. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller DD, Reimherr F, Kahn A, Cañive JM, Lieberman JA: Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services, 57:1110-1116, 2006.
26. Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Cañive JM, Lieberman JA: Components and correlates of family burden in schizophrenia. Psychiatric Services, 57:1117-1125, 2006.
27. Cañive JM, Miller GA, Moses SN, Irwin JG, Thoma RJ, Edgar JC, Sherwood A, Torres F, LaNoue M, Lewis S, Hanlon FM, Weisend MP, Mead V, Tuason VB: Effects of Olanzapine and Risperidone in schizophrenia: A randomized, double-blind crossover design. Psychopharmacology Bulletin, 39(1):105-116, 2006.
28. Westermeyer JJ, Cañive J, Crosby R, Thompson J: Remission from Pathological Gambling Among American Indian and Hispanic Veterans. Community Mental Health Journal, 42(6):537-553, 2006.
29. Keefe RSE, Bilder RM., Harvey PD, Davis S, Palmer B, Gold JM, Meltzer HY, Green MF, Miller D, Cañive JM, Adler Larry, Manschreck T, Swartz M, Rosenheck R, Perkins DO, Walker TM., Stroup TS, McEvoy JP, Lieberman JA: Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. Journal of Neuropsychopharmacology, 31(9):2033-2046, 2006.
30. Hanlon FM, Weisend MP, Hamilton DA, Jones AP, Thoma, RJ, Huang M, Martin K, Yeo RA, Miller GA, Canive JM: Impairment on the hippocampal-dependent virtual Morris water task in schizophrenia. Schizophrenia Research, 87(1-3):67-80, 2006.
31. Lu BY, Edgar JC, Jones AP, Smith AK, Huang, MX, Miller GA, Canive JM: Improved test-related reliability of 50 ms paired-click auditory gating magnetoencephalography source modeling. Psychophylsiology, 44(1):86-90, 2007.
32. Thoma RJ, Hanlon FM, Huang M, Moses SN, Weisend MP, Paulson KM, Irwin J, Edgar JC, Miller GA, Cañive JM: Impaired secondary somatosensory gating in patients with schizophrenia. Psychiatry Research, 151(3):189-199, 2007
33. Lu BY, Martin KE, Edgar JC, Smith AK, Lewis SF, Escamilla MA, Miller GA, Canive JM: Effect of catechol O-methyltransferase val158Met Polymorphism on the P50 gating endophenotype in schizophrenia. Biological Psychiatry, 62(7):822-825, 2007
34. Villarreal G, Calais L, Cañive JM, Lundy SL, Pickard J, Toney G: Villarreal G, Calais L, Cañive JM, Lundy SL, Pickard J, Toney G: Prospective Study to Evaluate the Efficacy of Aripiprazole as a Monotherapy in Patients with Severe Chronic Posttraumatic Stress Disorder: An Open Trial. Psychopharmacology Bulletin, 40(2):6-18, 2007
35. Brinker M, Westermeyer J, Thuras P, Canive J: Severity of combat-related posttraumatic stress disorder versus noncombat-related posttraumatic stress disorder: a community-based study in American Indian and Hispanic veterans. J Nerv Ment Dis, 195(8):655-61. 2007
36. Mayer AR, Franco AR, Sanchez N, Ling J, Canive JM: Assessment and quantification of head motion in neuropsychiatric functional imaging research as applied to schizophrenia J Int Neuropsychol Soc 13: 839-45, 2007
37. Keefe RSE, Bilder RM. Davis SM, Harvey PD, Palmer BW; Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy PJ, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, for the CATIE Investigators and the Neurocognitive Working Group: Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633-47, 2007.
38. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA; CATIE Investigators: Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 164:428-36, 2007.
39. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164:415-27, 2007.
40. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA, CATIE Investigators: Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry, 164(3):428-36, 2007.
41. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano G, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK, CATIE Investigators: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry,164(3):415-27, 2007.
42. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer JW, Gold JM, Meltzer HY, Greene, MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators Group; Neurocognitive Working Group: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial, Arch Gen Psychiatry. 64(6):633-47, 2007.
43. Ho RM, Ombao H, Edgar JC, Cañive, JM, Miller GA: Time-frequency discrimination analysis of MEG signals. NeuroImage, 40:174-186, 2008.
44. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA; for the CATIE Investigators. The effectiveness of antipsychotic medications in patients who use or avoid illicit
substances: Results from the CATIE study. Schizophr Res, 100(1-3):39-52, 2008.
45. Westermeyer J, Cañive J, Thuras P, Thompson J, Kim SW, Crosby RD, Garrard J: Mental health of non-gamblers versus “normal” gamblers among American Indian veterans: A community survey. J Gambl Stud, 24(2):193-205, 2008.
46. Thoma RJ, Hanlon FM, Sanchez NM, Petropoulos H, Jones A, Moses SN, Weisend MP, Huang M, Parks, L, Lundy SL, Smith A, Miller GA, Canive JM: Anterior hippocampal volume correlated with hemisphere-specific M50 sensory gating ratio. Psychophysiology, (In press).
47. Resnick SG, Rosenheck RA, Canive J, DeSouza C, Stroup TS, McEvoy J, Davis S, Keefe RSE, Swartz M, Lieberman J; CATIE Study Investigators Group: Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res, [Epub ahead of print]
48. Edgar J, Hanlon F, Huang M, Weisend M, Carpenter B, Hoechstetter K, Cañive J, Miller G: Superior temporal gyrus spectral abnormalities in schizophrenia. Psychophysiology, (In press).
Book Chapters & Reviews and Collaborative Papers
Lopez S, Kopelowicz A, Cañive JM: Strategies in developing culturally congruent family interventions for schizophrenia: The case of Hispanics. In H Lefley and D Johnson (eds): Family Interventions in Mental Illness: International perspectives. Westport, CT, London: Praeger. 2002.
Cañive JM, Thoma RJ, Huang MX: Neurofisiologia: Electroencefalografia y Magnetoencefalografia en el Estudio de Trastornos Psiquiatricos. In Leal C y Vallejo J, (eds): Tratado de Psiquiatria. Stm Editores, Madrid 2003 (January 2005).
Updated